Opinion

Video

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Author(s):

Robert Z. Orlowski, MD, PhD,Jonathan L. Kaufman, MD

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Related Videos
2 KOLs are featured in this series.
Douglas W. Sborov, MD, MS
2 KOLs are featured in this series.
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
David R. Oveisi, MD
November 20th 2024

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Multiple myeloma Image credit: LASZLO – stock.adobe.com
November 15th 2024

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

LASZLO – stock.adobe.com
November 14th 2024

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy